Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415625 | 0.81 | EGLN3 (0.62) | ALDH1A1EGLN3TBXAS1L3MBTL1 | |
| SCHEMBL7006174 | 0.81 | ALDH1A1 (0.66) | ALDH1A1EGLN3CYP19A1KDM4EAHR | |
| SCHEMBL77978 | 0.79 | — | — | |
| SCHEMBL8429681 | 0.78 | ALDH1A1 (0.61) | ALDH1A1EGLN3CYP19A1KDM4EAHR | |
| SCHEMBL27785516 | 0.78 | ALDH1A1 (0.96) | ALDH1A1EGLN3CYP19A1TBXAS1HMOX2 | |
| SCHEMBL1179222 | 0.78 | — | — | |
| Bromide SCHEMBL6988476 | 0.78 | ALDH1A1 (0.96) | ALDH1A1EGLN3CYP19A1TBXAS1HMOX2 | |
| Hydrochloric Acid SCHEMBL1904485 | 0.78 | ALDH1A1 (0.96) | ALDH1A1EGLN3CYP19A1TBXAS1HMOX2 | |
| SCHEMBL28119672 | 0.78 | ALDH1A1 (0.96) | ALDH1A1EGLN3CYP19A1TBXAS1HMOX2 | |
| SCHEMBL7241523 | 0.77 | ALDH1A1 (0.72) | ALDH1A1EGLN3CYP19A1ALPIALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185575-B1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-116234801-A | Heteroaryl-methyl substituted triazoles as vasopressin receptor V1A antagonists | 豪夫迈·罗氏有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4185575-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-105890063-B | Vertical air eliminator | 刘世超 | 2019-04-05 | — | — | CN | disclosed |
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
| WO-2017081615-A1 | 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2017-05-18 | — | — | WO | disclosed |
| CN-106004353-A | Vehicle-mounted air purification device | 刘世超 | 2016-10-12 | — | — | CN | disclosed |
| CN-105890063-A | Three-dimensional air purifier | 刘世超 | 2016-08-24 | — | — | CN | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| EP-0396769-B1 | AZOXY COMPOUND | KOWA CO. LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| US-5093480-A | Fungicides | KOWA COMPANY, LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| EP-0396769-A1 | AZOXY COMPOUND | KOWA CO. LTD. (JP) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | CYP3A43, CYP3A4, CYP4B1 | ALDH1A1 943/4885EGLN3 985/4885CYP19A1 58/4885 |
| US-20180282331-A1 | 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | TST, THPO, STS | ALDH1A1 2258/4885EGLN3 2446/4885CYP19A1 1843/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | ALDH1A1 313/4885EGLN3 4528/4885CYP19A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.